Insider transactions

EDGAR

PDS BIOTECHNOLOGY CORPORATION

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–14 of 14

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-18 Filed 2026-10-21Dawson John Andrew Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (22,700) — exercise price 1.13
Acquired (A)22,7000.00
0

Derived: shares × price per share. Exact value 0.00.

22,700Direct (D) No
F1
  • F1 The Stock Option shall vest in three (3) equal annual installments beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such dates.
Open filing 0001140361-26-040424 Read from the filing’s XML Dispute this row
2026-10-18 Filed 2026-10-20Ramsdell Deborah Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (22,700) — exercise price 1.13
Acquired (A)22,7000.00
0

Derived: shares × price per share. Exact value 0.00.

22,700Direct (D) No
F1
  • F1 The Stock Option shall vest in three (3) equal annual installments beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such dates.
Open filing 0001140361-26-040294 Read from the filing’s XML Dispute this row
2026-10-18 Filed 2026-10-20Wendel Bruce Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (22,700) — exercise price 1.13
Acquired (A)22,7000.00
0

Derived: shares × price per share. Exact value 0.00.

22,700Direct (D) No
F1
  • F1 The Stock Option shall vest in three (3) equal annual installments beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such dates.
Open filing 0001140361-26-040292 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Boesgaard Lars Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 0.98
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Open filing 0001140361-26-007646 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Toutain Stephan Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 0.98
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Open filing 0001140361-26-007644 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03BRAWLEY OTIS W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (54,876) — exercise price 0.98
Acquired (A)54,8760—54,876Direct (D) No
F1
  • F1 The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Open filing 0001140361-26-007640 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03BEDU-ADDO FRANK Director · Officer: President/CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (548,782) — exercise price 0.98
Acquired (A)548,7820—548,782Direct (D) No
F1
  • F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Open filing 0001140361-26-007649 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Shepard Kirk V. Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 0.98
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Open filing 0001140361-26-007647 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03CONN GREGORY Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (150,000) — exercise price 0.98
Acquired (A)150,0000—150,000Direct (D) No
F1
  • F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Open filing 0001140361-26-007648 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Iliev Ilian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (54,876) — exercise price 0.98
Acquired (A)54,8760—54,876Direct (D) No
F1
  • F1 The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Open filing 0001140361-26-007642 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Glover Stephen C. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (54,876) — exercise price 0.98
Acquired (A)54,8760—54,876Direct (D) No
F1
  • F1 The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Open filing 0001140361-26-007639 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Brown Spencer D. Officer: Senior VP, General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (300,000) — exercise price 0.98
Acquired (A)300,0000—300,000Direct (D) No
F1
  • F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Open filing 0001140361-26-007645 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Ali-Jackson Kamil Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (54,876) — exercise price 0.98
Acquired (A)54,8760—54,876Direct (D) No
F1
  • F1 The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Open filing 0001140361-26-007641 Read from the filing’s XML Dispute this row
2026-01-12 Filed 2026-03-03Freitag Gregory Gene Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (54,876) — exercise price 0.98
Acquired (A)54,8760—54,876Direct (D) No
F1
  • F1 The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Open filing 0001140361-26-007643 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Nant Capital, LLC Common Stock, par value $0.00033 per share19.922,856,453.0011/09/2026 Filed 2026-11-12SCHEDULE 13D/AAmendment 1Open filing 0001193125-26-456632 Dispute this row
Patrick Soon-Shiong Common Stock, par value $0.00033 per share19.922,856,453.0011/09/2026 Filed 2026-11-12SCHEDULE 13D/AAmendment 1Open filing 0001193125-26-456632 Dispute this row
Nant Capital, LLC Common Stock, par value $0.00033 per share19.920,336,33509/14/2026 Filed 2026-09-21SCHEDULE 13DOpen filing 0001193125-26-397073 Dispute this row
Patrick Soon-Shiong Common Stock, par value $0.00033 per share19.920,336,33509/14/2026 Filed 2026-09-21SCHEDULE 13DOpen filing 0001193125-26-397073 Dispute this row
Armistice Capital, LLC Common Stock, par value $0.00033 per share4.992,283,288.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-25-003567 Dispute this row
Steven Boyd Common Stock, par value $0.00033 per share4.992,283,288.0006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 1Open filing 0001172661-25-003567 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,137,454 filings read, dated 2004-06-14 to 2026-11-16: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202260,488
2023199,811
2024209,823
2025235,520
2026254,873

Filings made before the SEC required XML are listed, not extracted.

Back to PDS BIOTECHNOLOGY CORPORATION